Summary
Dwarfbody-Therapeutics (DB-Tx) is a new company, established in 2016 as a spin off from a frontrunner research team in Gastro-Intestinal Cancers in the AMC Amsterdam. DB-Tx aims to transform current, ineffective treatment of these aggressive cancer types by co-administering highly effective and safe low molecular weight antibodies (“Dwarfbodies®”) to significantly increase therapeutic outcome. The superiority of the Dwarfbodies® compared to competing molecules and their anticancer effects have been published in various high ranked journals. Now PANTREAT primarily aims at broadening the initial target market for the Dwarfbodies® by creating additional proof-of-concept, reports on production, test Trial Centers and a sound business plan. Results will be compiled into a sound company portfolio, which will form the basis for further development of the Dwarfbodies® and obtaining investments and supportive grants and partnerships. Finally, this will lead to highly attractive licencing deals from 2020 onwards.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/763138 |
| Start date: | 01-03-2017 |
| End date: | 31-08-2017 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Dwarfbody-Therapeutics (DB-Tx) is a new company, established in 2016 as a spin off from a frontrunner research team in Gastro-Intestinal Cancers in the AMC Amsterdam. DB-Tx aims to transform current, ineffective treatment of these aggressive cancer types by co-administering highly effective and safe low molecular weight antibodies (“Dwarfbodies®”) to significantly increase therapeutic outcome. The superiority of the Dwarfbodies® compared to competing molecules and their anticancer effects have been published in various high ranked journals. Now PANTREAT primarily aims at broadening the initial target market for the Dwarfbodies® by creating additional proof-of-concept, reports on production, test Trial Centers and a sound business plan. Results will be compiled into a sound company portfolio, which will form the basis for further development of the Dwarfbodies® and obtaining investments and supportive grants and partnerships. Finally, this will lead to highly attractive licencing deals from 2020 onwards.Status
CLOSEDCall topic
SMEInst-05-2016-2017Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
